Capital Com MENA Securities Trading LLC is regulated by the Capital Market Authority.
Open platformOpen platform

Fleury Signs Deal for Atlântica to Take 49.99% Stake in Oncology Venture

By Public Technologies
  • Fleury signed a binding memorandum on November 10, 2026, for related party Atlântica to invest in its outpatient oncology business, FleuryOnco.
  • Planned investment totals R$ 72 million through 2027, with FleuryOnco ownership split 50.01% for its parent and 49.99% for Atlântica.
  • The business will comprise seven oncology clinics in São Paulo and Rio de Janeiro, opening between 2026 and 2027.
  • Atlântica is affiliated with Bradesco Diagnóstico, which holds 24.85% of the parent company's common shares.
  • Closing remains subject to CADE approval and definitive agreements.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fleury SA published the original content used to generate this news brief on November 10, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.